e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Asthma management
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A longitudinal follow-up of severe asthma patients receiving reslizumab
P. Chanez (Marseille, France)
Source:
International Congress 2017 – Asthma management
Session:
Asthma management
Session type:
Thematic Poster
Number:
3970
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Chanez (Marseille, France). A longitudinal follow-up of severe asthma patients receiving reslizumab. 3970
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Follow-up of patients with severe asthma receiving reslizumab: an FEV1 analysis
Source: International Congress 2017 – Asthma management
Year: 2017
The 1-year cost-effectiveness of roflumilast for the treatment of severe to very severe COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 194s
Year: 2007
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
“App” for uncontrolled moderate-severe asthma patients follow-up
Source: International Congress 2017 – Biomarker-based asthma control
Year: 2017
Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece.
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 30s
Year: 2006
Follow-up of patients with moderate-severe allergic asthma treated with omalizumab
Source: Annual Congress 2010 - Asthma: clinical aspects and treatment
Year: 2010
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV
1
in patients with severe persistent allergic asthma irrespective of age
Source: Eur Respir J 2005; 26: Suppl. 49, 48s
Year: 2005
Stop omalizumab: a multicenter follow up study after discontinuation in pediatric patients with severe asthma
Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches
Year: 2021
Evolution of patients with severe asthma treated with mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010
The treatment with flunisolide in severe steroid asthmatics: the three-year follow-up study
Source: Eur Respir J 2001; 18: Suppl. 33, 47s
Year: 2001
Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004
Mild improvement in symptoms and pulmonary function in a long-term follow-up of patients with TDI-induced asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 604s
Year: 2005
Outcomes over the first two years of treatment with mepolizumab in severe asthma
Source: Eur Respir J, 58 (6) 2101313; 10.1183/13993003.01313-2021
Year: 2021
A ten year follow-up of former paediatric asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 233s
Year: 2005
Evaluating the efficacy of omalizumab in severe persistent asthma patients
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017
Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey
Source: Eur Respir J 2013; 42: 1224-1233
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept